BRNS
Barinthus BiotherapeuticsBRNS
BRNS
$1.28
4.07%
Market Cap: $50.5M
About: Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
Employees: 130
0
Funds holding %
of 6,686 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
20% more funds holding
Funds holding: 15 [Q1] → 18 (+3) [Q2]
0.45% more ownership
Funds ownership: 24.95% [Q1] → 25.4% (+0.45%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
45% less capital invested
Capital invested by funds: $21.4M [Q1] → $11.8M (-$9.62M) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$3
134%
upside
Avg. target
$5.83
356%
upside
High target
$9.50
642%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Alliance Global Partners | 642%upside $9.50 | Buy Maintained | 13 Aug 2024 |
HC Wainwright & Co. Yi Chen 32% 1-year accuracy 44 / 139 met price target | 291%upside $5 | Buy Reiterated | 12 Aug 2024 |
Barclays Carter Gould 64% 1-year accuracy 21 / 33 met price target | 134%upside $3 | Overweight Maintained | 13 Jun 2024 |